Chemotherapy may lead to mitochondrial dysfunction in skeletal muscle
Share

Rockville, Md. (October 4, 2018)–Chemotherapy drugs to treat breast cancer may promote muscle mitochondrial dysfunction, according to new research. Dysfunctional mitochondria, the energy centers of the cells, may contribute to fatigue and weakness that some people with breast cancer experience through the course of disease treatment. The study is published ahead of print in the American Journal of Physiology–Cell Physiology.

Breast cancer, the most commonly diagnosed cancer in the U.S., has been considered one of the less-damaging cancers in terms of severe muscle wasting and weight loss (cachexia). However, some people with breast cancer may also suffer from muscle loss and fatigue that limits their daily activities. There is limited research on the effect of breast cancer and its treatments on the muscles in human patients.

Researchers from the University of Vermont compared muscle fibers from women with breast cancer who were undergoing chemotherapy after surgical removal of cancerous tumors. The women had a lower cross-sectional area of muscle fibers–an indication of muscle loss–when compared to a healthy control group. A reduced number of mitochondria was also seen in the cancer group.

The research team also treated mouse muscle cells with the chemotherapy drugs doxorubicin and paclitaxel, medications that

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD